ASCO GU 2018: Adding immunotherapy to standard treatment slows growth of advanced kidney cancer, with fewer side effects

In a phase III clinical trial of people with previously untreated metastatic renal cell cancer (mRCC), combining immunotherapy atezolizumab with targeted therapy bevacizumab delayed cancer growth by about three months longer than sunitinib, another...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2BF0Opv
via IFTTT